Keith Kurlander

Is it a drug?

Is it a therapy sessions?

Like, what does it involve if, like, let's say they were to undergo these treatments?

You know, you described earlier psychedelics is not, you know, taking LSD out in our lawn, listening to, you know, Grateful Dead.

How do we get from that fringe counterculture of the 60s, you know, to what that was viewed of psychedelics, LSD, mushrooms, all those, to where we are today, where we're clearing phase three FDA trials?

What was kind of the tipping point that the medical establishment said, all right, this is actually a serious therapy?

So whenever we get kind of an industry breakthrough like this, you know, investors tend to flood in.

It's the next hot thing, the next big thing.

And this arguably so can become a very, very big thing.

You stated some of the market potential there.

When you look at kind of the suitability as an investment in this industry right now, what are kind of the red flags individual investors should be watching for?

I'll kick that to you, Keith.

Yeah, it's interesting you mention that because, you know, when we look at companies, we look for kind of a moat, you know, a competitive advantage that these companies have.

Traditional biopharma, you know, they have patents and then those last for a very long time.

No one else can produce them.

In this industry, where do you think, and you touched on it briefly, where do you think some of those moats or competitive advantages will be?

Will it be like synthetic patents like Comp360, the clinics, the therapy protocols?

Where do you think that advantage will be?

So I want to kind of help ground it for listeners.

What's kind of a real world story that kind of captures very heart of your argument that you make in your book?